Nisa Investment Advisors
CYTK icon

Nisa Investment Advisors’s Cytokinetics CYTK Stock Holding History

Nisa Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
12,705
+736
+6% +$52.8K ﹤0.01% 769
2026
Q1 		$789K Buy
11,969
+506
+4% +$32.2K ﹤0.01% 849
2025
Q4 		$728K Sell
11,463
-68
-0.6% -$4.23K ﹤0.01% 908
2025
Q3 		$634K Buy
11,531
+1,338
+13% +$55.1K ﹤0.01% 964
2025
Q2 		$337K Sell
10,193
-4,606
-31% -$160K ﹤0.01% 1087
2025
Q1 		$595K Buy
14,799
+107
+0.7% +$4.92K ﹤0.01% 954
2024
Q4 		$691K Sell
14,692
-370
-2% -$19.2K ﹤0.01% 975
2024
Q3 		$795K Buy
15,062
+430
+3% +$24K ﹤0.01% 911
2024
Q2 		$793K Buy
14,632
+7
+0% +$423 0.01% 938
2024
Q1 		$1.03M Sell
14,625
-5,676
-28% -$439K 0.01% 874
2023
Q4 		$1.69M Buy
20,301
+11
+0.1% +$398 0.01% 707
2023
Q3 		$598K Sell
20,290
-5
-0% -$167 ﹤0.01% 1016
2023
Q2 		$662K Buy
20,295
+4,590
+29% +$170K ﹤0.01% 995
2023
Q1 		$553K Sell
15,705
-60
-0.4% -$2.45K ﹤0.01% 1038
2022
Q4 		$722K Sell
15,765
-100
-0.6% -$4.3K 0.01% 1006
2022
Q3 		$755K Buy
15,865
+155
+1% +$7.46K 0.01% 902
2022
Q2 		$617K Buy
15,710
+3,500
+29% +$141K 0.01% 979
2022
Q1 		$449K Sell
12,210
-2,585
-17% -$91.8K ﹤0.01% 1116
2021
Q4 		$491K Buy
14,795
+2,095
+16% +$80.8K ﹤0.01% 1016
2021
Q3 		$454K Buy
12,700
+2,080
+20% +$61.2K ﹤0.01% 1148
2021
Q2 		$210K Hold
10,620
– – ﹤0.01% 1390
2021
Q1 		$247K Buy
10,620
+2,020
+23% +$43.1K ﹤0.01% 1413
2020
Q4 		$179K Sell
8,600
-1,350
-14% -$24.7K ﹤0.01% 1515
2020
Q3 		$215K Buy
9,950
+2,150
+28% +$50.3K ﹤0.01% 1283
2020
Q2 		$184K Buy
7,800
+300
+4% +$5.63K ﹤0.01% 1299
2020
Q1 		$88K Hold
7,500
– – ﹤0.01% 1405
2019
Q4 		$80K Buy
+7,500
New +$77K ﹤0.01% 1469

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nisa Investment Advisors's CYTK Position: Q2 2026 in Review

Nisa Investment Advisors increased its Cytokinetics (CYTK) stake by 6.1% in Q2 2026, buying an estimated $52.8K and bringing the position to 12,705 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Nisa Investment Advisors first reported a position in CYTK in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.69M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Nisa Investment Advisors held 12,705 shares of Cytokinetics worth $1.08M as of Q2 2026.
  • Nisa Investment Advisors bought 736 Cytokinetics shares in Q2 2026, an estimated $52.8K.
  • Cytokinetics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #769 holding.
  • Nisa Investment Advisors first reported a position in Cytokinetics in Q4 2019 and has held it in 27 quarters since.
  • Nisa Investment Advisors's Cytokinetics position peaked at $1.69M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.